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Abstract
Background: Neurofibromatosis Type 1(NF-1) has autosomal dominant inheritance with complete penetrance,
variable expression and a high rate of new mutation. Pheochromocytoma occurs in 0.1%-5.7% of patients with
NF-1.
Case presentation: We present the case of a 37-year-old patient with laparoscopically resected
pheochromocytoma. He was investigated for hypertension, flushing and ectopic heart beat. Abdominal CT and MRI
revealed a mass measuring 8 × 4 cm in the right adrenal gland. The diagnosis of pheochromocytoma was
confirmed by elevated 24-hour urine levels of VMA, metanephrines and catecholamines as well as positive MIBG
scan. The patient presented with classic clinical features of NF-1, which was confirmed by pathologic evaluation of
an excised skin nodule. The patient underwent laparoscopic right adrenalectomy through a transabdominal
approach and was discharged on the second postoperative day, being normotensive. The patient is normotensive
without antihypertensive therapy 11 years after the procedure.
Conclusion: Nowadays in the era of laparoscopy, patients with pheochromocytoma reach the operating theatre
easier than in the past. Despite, the feasibility and oncological efficacy of the laparoscopic approach to the
adrenals, continued long term follow-up is needed to establish the minimally invasive technique as the preferred
approach. Furthermore, these patients should be further investigated for other neoplasias and stigmata of other
neurocutaneous syndromes, taking into account the association of the familial pheochromo-cytoma with other
familial basis inherited diseases.
Background
Pheochromocytomas are tumors of the adrenal medulla
and extra-adrenal chromaffin tissue that secrete catecho-
lamines, resulting in hypertension, whether sustained or
paroxysmal, and other symptoms of increased produc-
tion of catecholamines [1-3]. They may be classified as
sporadic or familial. Most of the pheochromocytomas
are sporadic [4]. Familial predisposition is seen mainly
in patients with multiple endocrine neoplasia type 2,
neurofibromatosis Type 1 (NF-1), von Hippel-Lindau
disease and familial carotid body tumors [5].
NF-1 affects approximately 1 in 3500 individuals
worldwide and it has autosomal dominant inheritance
with complete penetrance [6]. Pheochromocytoma
occurs in 0.1%-5.7% of patients with NF-1 [7]. The only
treatment of pheochromocytoma is surgical removal [1].
The traditional open approach (either transabdominal,
or retroperitoneal) has been replaced by the laparo-
scopic transabdominal and the endoscopic retroperito-
neal procedure.
Despite the feasibility and oncological efficacy of the
laparoscopic approach to the adrenals, continued long-
term follow-up is needed to establish the minimally
invasive technique as the preferred approach [8,9].
Herein, we present a case of a patient with NF-1 and
pheochromocytoma, who was successfully treated with
laparoscopic right adrenalectomy 11 years ago.
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A 37-year-old patient in good general condition (height:
175 cm, weight: 70 kg), was admitted to our hospital for
surgical treatment of a diagnosed pheochromocytoma.
The patient reported that during last year the family
physician had repeatedly diagnosed hypertensive epi-
sodes, accompanied by intermittent attacks of severe
flushing, perspiration and ectopic heart beat. During the
hospital stay blood pressure was closely monitored, fluc-
tuating between 125/80 and 190/110 mmHg. The ECG
revealed sinus arrhythmia.
Clinical examination revealed liver enlargement, café-
au-lait spots and skin nodules. NF-1 was confirmed by
pathologic evaluation of an excised skin nodule which
revealed a neurofibroma. The medical history revealed
pulmonary tuberculosis during childhood, which was
treated with six month multiple drug therapy. Compu-
terized tomography of the abdomen showed a round
tumor, 8 × 4 cm in diameter, which could be clearly
delineated from the right kidney. The I131 MIBG scan
revealed the presence of chromafinic tissue only in the
right adrenal.
Laboratory tests revealed elevated catecholamine,
metanephrine and vanillylmandelic acid (VMA) levels in
t h e2 4 - hu r i n ec o l l e c t i o n( T a b l e1 ) .T h ep l a s m al e v e lo f
adrenaline and cortisone were within normal limits.
Thyroid and parathyroid ultrasonography was normal.
Serum calcitonin levels were 8.5 pg|ml (normal range:
8-10 pg/ml), whereas serum parathormone levels were
18.3 pg|ml (range: 8-76 pg/ml). Pituitary CT scan was
normal.
The patient preparation for the operative procedure
with alpha-blocking agents started ten days before the
procedure and with beta-blockers three days before it.
A pacemaker was inserted to control the heart rate dur-
ing the procedure. Laparoscopic adrenalectomy was per-
formed with transabdominal approach. The patient was
placed in a left lateral position. The intraoperative moni-
toring included continuous ECG control, invasive blood
pressure recording, pulse oximetry and capnography.
During the mobilization of the tumor and prior to the
adrenal vein ligation, arterial blood pressure rose to
250/130 mmHg, whereas blood gases remained normal.
The hypertension was treated with continuous intrave-
nous infusion of nitroglycerine (0.1-0.5 mg/min) and
hydralazine 5 mg increments. The patient was extubated
immediately after the operation and transferred to a
surgical ward monitored with noninvasive blood pres-
sure monitor. He was discharged a day after.
The pathological evaluation of the tumor confirmed
the diagnosis of pheochromocytoma. Urine catechola-
mines, metanephrines and VMA returned to normal on
the 7th postoperative day. The patient is normotensive
without antihypertensive therapy 11 years after the
procedure.
Discussion
Pheochromocytoma is found in 0.1% among those tested
because of hypertension [1] and in 4% of patients with
adrenal incidentaloma [2]. The incidence in the general
population is estimated to be 1 per 100,000 persons per
year or less [3] and approximately 10% of patients have
bilateral pheochromocytomas [4]. Moreover, approxi-
mately 10% of pheochromocytomas are malignant at diag-
nosis; however this is not determined at the time of
diagnosis [4]. Many malignant pheochromocytomas are
f o u n dt ob em a l i g n a n to n l yb yt h ef a c tt h a tt h e yr e c u r
after a complete gross resection [4]. Most of them are
sporadic. Approximately 10-15% of the cases have been
thought to be due to hereditary causes [4]. Familial predis-
position is seen mainly in patients with Multiple Endo-
crine Neoplasia (MEN) type 2, NF-1, von Hippel-Lindau
disease and familial carotid body tumors (Table 2) [5].
Unilateral or bilateral pheochromocytomas are found
in 50% of patients with MEN 2 syndrome [10]. Pheo-
chromocytomas associated with MEN 2A are diagnosed
concurrently with MTC in 35-73% of the cases and as
the first manifestation of MEN 2A in 9-27% of them [4].
MEN 2A patients are statistically significantly younger
at age of pheochromocytoma diagnosis than patients
with sporadic pheochromocytoma (mean ages of 38 and
47 years, respectively) [11-14].
NF-1 was described by Smith in 1849 and von Recklin-
ghausen in 1882 [15]. It affects approximately 1 in 3500
individuals worldwide and it has autosomal dominant
inheritance with complete penetrance, variable expression
and a high rate of new mutation, approximately 50%,
which is the highest rate of new mutation of any known
s i n g l e - g e n ed i s o r d e r[ 1 6 , 6 ] .T h eN F - 1g e n ei sat u m o r
suppressor gene mapping to chromosome 17q11.2.
Table 1 24 hour urinary metabolites level
Sample Value Normal Value
Catecholamines 808 μg 14 - 108
Metanephrines 3.5 mg < 1
VMA 36 mg 1.8 - 6.7
Table 2 Hereditary Forms of Pheochromocytoma
Syndrome Frequency of
Pheo (%)
Gene Chromosome
location
MEN type II 30-50 RET oncogene 10q11
VHL disease 15-20 VHL tumor
suppressor gene
3p25
NF type 1 1-5 Neurofibromatosis
type 1
17q11
Familial carotid
body tumors
Paraganglioma 11q21-23
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extending over 300 kb of genomic DNA), mutation analy-
sis has been difficult (in only about 15% of patients muta-
tions are identified) [17]. The diagnosis of NF-1 is based
on criteria developed by National Institutes of Health
Consensus Conference in 1987 [18-20]. Pheochromocy-
toma occurs in 0.1%-5.7% of patients with NF-1, and in
20%-50% of NF-1 patients with hypertension, compared
to 0.1% of all hypertensive individuals [7]. The mean age
at diagnosis of pheochrocytoma in patients with NF-1 is
42 years [7]. Persons with NF-1 are at increased risk for
malignant conditions, especially malignant peripheral
nerve sheath tumor (MPNST), leukemia and rhabdomyo-
sarcoma [17].
Von Hippel-Lindau (VHL) disease, an autosomal domi-
nant syndrome [4], is clinically subdivided into two types:
those without Pheo (VHL type 1) and those with Pheo
(VHL type 2). Type 2 VHL disease, where pheochromo-
cytoma develops, accounts for 10% of VHL disease cases
[21,22]. The largest series of VHL patients with pheo-
chromocytomas was described by Walther et al [23]. The
mean age at diagnosis was 29.9 year, which was statisti-
cally significantly younger than the mean age at diagnosis
in a control group of patients with sporadic pheochromo-
cytoma (39.7 years)[24]. However, there may be bias due
to routine screening in the VHL group [4].
The treatment of functioning adrenal tumors is surgical
removal of the affected gland first described by Sargent in
1914 [25]. Since 1992 [26] laparoscopic adrenalectomy
(LA) has gained field in the surgery of the adrenals and
nowadays it is the procedure of choice [1,27,28]. Modern
indications for LA have been expanded to large tumors,
bilateral pathology and metastatic malignancies [28,29].
The feasibility and oncological efficacy of the laparo-
scopic approach to the adrenals have been reported in
cases of malignancy; however, continued long-term fol-
low-up is needed to establish the minimally invasive
technique as the preferred approach [8,9]. The only abso-
lute contraindication to LA currently remains large neo-
plastic lesions with involvement of the surrounding
anatomical structures, a condition that should be treated
using an open approach [27]. In this case, the tumor had
intact contour, was homogeneous and based on CT scan
was considered benign.
Early ligation of the central adrenal vein to facilitate
pharmacologic control in pheochromocytoma has been
emphasized in reports and textbooks. However, our
experience and that of others indicate that early ligation of
the adrenal vein is not always feasible because of the pos-
terior entrance to the cava on the right and the medial
entrance to the renal vein on the left. Our patient devel-
oped intraoperative hypertension, successfully treated. An
extensive search of the literature showed that hemody-
namic instability was routinely successfully treated [27,30].
From a technical standpoint, large adrenal masses are diffi-
cult to dissect laparoscopically. In our series the largest
tumor laparoscopically resected was a 14 cm myelolipoma.
Laparoscopic approach to large adrenal tumors, less than
15 cm in size, is feasible but necessitates experience in
laparoscopic and adrenal surgery. Conversion can always
be an option, and it is not considered to be a complication.
Conclusions
In the era of laparoscopy, approach to patients with
pheochromocytoma is easier than in the past. These
patients should be further investigated for other neopla-
sias (such as thyroid carcinoma, parathyroid hyperplasia,
central and peripheral nervous tumors) and stigmata of
other neurocutaneous syndromes (v. Hippel Lindau dis-
ease), taking into account the association of the familial
pheochromo-cytoma with other familial basis inherited
diseases.
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